Overview
Cell therapy firm's Q4 revenue slightly missed analyst expectations
Adjusted EPS for Q4 beat analyst expectations
Company achieved CARVYKTI franchise profitability for full year 2025
Outlook
Legend Biotech expects to achieve operating profit in 2026
Company is expanding CARVYKTI availability in community settings
Legend Biotech focuses on advancing in vivo and allogeneic programs
Result Drivers
CARVYKTI SALES - Significant increase in CARVYKTI sales contributed to higher collaboration revenue
GLOBAL EXPANSION - CARVYKTI now available in 14 markets across 294 sites, expanding global footprint
PIPELINE ADVANCEMENT - Advanced early-stage cell therapy portfolio with first patient dosing and new clinical data
Company press release: ID:nGNX1thDhQ
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Slight Miss* | $306.30 mln | $306.87 mln (13 Analysts) |
Q4 Adjusted EPS | Beat | $0.01 | -$0.11 (7 Analysts) |
Q4 EPS | -$0.08 | ||
Q4 Net Income | -$30.90 mln | ||
Q4 Pretax Profit | -$19.70 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Legend Biotech Corp is $69.50, about 263.1% above its March 9 closing price of $19.14
The stock recently traded at 58 times the next 12-month earnings vs. a P/E of 82 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)